<DOC>
	<DOCNO>NCT01542619</DOCNO>
	<brief_summary>This first man , prospective , single-center , randomize , double-blind , dose-escalation cohort study investigate tolerability , safety pharmacokinetics rVIIa-FP comparison placebo .</brief_summary>
	<brief_title>A Safety Pharmacokinetics Study Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin ( rVIIa-FP ) Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male subject 18 35 year age , inclusive . Body weight 50.0 100.0 kg , inclusive . Body mass index ( BMI ) 18.0 29.9 kg/m2 , inclusive . Written inform consent study participation obtain undergo study specific procedure . Subjects increase cardiovascular risk . Any clinical sign know history atherosclerosis thromboembolic event . A subject consider high risk thromboembolic event confirm either history thrombophilia screen test . Subjects significant elevation cholesterol level . Renal dysfunction . Overt bleeding . Smokers positive cotinine test screening . Participation trial investigate procoagulant within last six month prior screen . Known suspected hypersensitivity investigational medicinal product ( IMP ) , excipients IMP . Contraindications Warfarin ( CoumadinÂ® ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>